There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

Another consideration is that the effect on disease progression was pretty ... Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that ...

“It is not yet clear whether there may be a subgroup of people with Parkinson’s disease who may get benefit from the use of exenatide,” he added. He said that there will be more research to ...

Medscape Medical News, February 21, 2025 Despite Early Promise GLP-1 Disappoints in Parkinson’s Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite ...

Brought into the limelight by actor Michael J. Fox, Parkinson's disease affects the body's ability to control movement. The most prominent signs of Parkinson's disease result from damage to brain ...

A study involving over 1,600 patients reveals that Parkinson's disease diagnoses are frequently revised, with 13.3% changing over a 10-year period, increasing to 17.7% when considering dementia ...